Home › Compare › STEAF vs ABBV
STEAF yields 1.35% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, STEAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STEAF + ABBV for your $10,000?
Stream Media Corporation engages in the CS broadcasting, management, mobile, fan club, merchandising, events and concerts, music, and rights businesses primarily in Japan and South Korea. The company operates KNTV, a Korean entertainment channel, and EC site that focuses on Korean Wave goods comprising music and video software products; plans and produces original programs; broadcasts music live performances and online fan meeting events; manages the activities of artists in Japan; plans and organizes activities, including music and appearances at events in the media and in commercials; plans and operates the official mobile sites of the carriers; and operates and plans artists' fan club sites. It is also engaged in product planning and sale of goods related to the artists of K1stshop and SMTOWN FC GOODS ONLINE STORE; and design, creation, and sale of event goods that are sold at concerts, fan meetings, and other events, as well as sells goods on commission. In addition, the company acquires broadcasting, distribution, and other associated rights for image contents, including dramas and movies, as well as operates relevant businesses comprising distribution and DVD business; and plans and holds events related to artists and their fan clubs, and dramas. Stream Media Corporation was incorporated in 1971 and is headquartered in Tokyo, Japan.
Full STEAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.